Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$460 Mln
P/E Ratio
--
P/B Ratio
1.34
Industry P/E
--
Debt to Equity
0.02
ROE
-0.32 %
ROCE
-30.88 %
Div. Yield
0 %
Book Value
5.83
EPS
-1.47
CFO
$-134.55 Mln
EBITDA
$-176.76 Mln
Net Profit
$-160.37 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tyra Biosciences (TYRA)
| -35.83 | -22.43 | -44.77 | -39.17 | -3.35 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Tyra Biosciences (TYRA)
| 0.36 | 82.24 | -45.98 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design... through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. Address: 2656 State Street, Carlsbad, CA, United States, 92008 Read more
Co-Founder, President, CEO, Secretary, Treasurer & Director
Dr. Todd Harris Ph.D.
Co-Founder, President, CEO, Secretary, Treasurer & Director
Dr. Todd Harris Ph.D.
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tyra Biosciences Inc (TYRA) stood at $ 364 Mln as on 31-Dec-24
The share price of Tyra Biosciences Inc (TYRA) is $8.92 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Tyra Biosciences Inc (TYRA) has given a return of -3.35% in the last 3 years.
Tyra Biosciences Inc (TYRA) has a market capitalisation of $ 460 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tyra Biosciences Inc (TYRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tyra Biosciences Inc (TYRA) and enter the required number of quantities and click on buy to purchase the shares of Tyra Biosciences Inc (TYRA).
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. Address: 2656 State Street, Carlsbad, CA, United States, 92008
The CEO & director of Dr. Todd Harris Ph.D.. is Tyra Biosciences Inc (TYRA), and CFO & Sr. VP is Dr. Todd Harris Ph.D..
There is no promoter pledging in Tyra Biosciences Inc (TYRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Tyra Biosciences Inc. (TYRA) | Ratios |
|---|---|
|
Return on equity(%)
|
-31.6
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tyra Biosciences Inc (TYRA) was $0 Mln.
$0.31
(
